Two Labs Blog

Two Labs Blog

Two Labs Joins Global Celebration of Rare Disease Day

Posted by Jessica Krauser on February 28, 2019

DSC_0423Since 2008, Rare Disease Day has been on the last day of February – which every four years is a rare 29th of the month. The observance was created to drive awareness of the 6,000 existing rare diseases that affect 1 in every 20 of us.

As a way of demonstrating our support, we joined in on Rare Disease Day’s face-painting event at our offices, along with donations to Rare Disease Day and the National Organization for Rare Disorders to help further the amazing work.DSC_0416

Check out some photos from the event and join in to #ShowYourRare on social media! We’d also encourage you to check out some of the inspiring testimonials on Rare Disease Day’s website.

We're also supporting Mediaplant in the campaign for Rare Diseases by bringing awareness to the challenges manufacturers, regulators and payers face with orphan drug market access. 

IMG_0504

 

This year, the theme is “Bridging health and social care,” which is something that is extremely meaningful to us at Two Labs. In recent years, we’ve become increasingly involved in rare disease drug launches across the globe and we’ve seen how much support and assistance is needed by those suffering from rare diseases.  While the innovation and progress with rare diseases are very impressive, we can’t forget what our work is really about – improving people’s lives.

Topics: MKO, Pennside Partners, Rare Disease Day

Key Learnings on Pathways of Care

Posted by Two Labs | MKO Global Partners on August 1, 2018

Oncology is a high cost and high management priority disease state for US payers, however, ability to control cost in this space is limited. MKO Global Partners, a Two Labs Company, conducted previous research that suggests oncology drugs are primarily managed to label and only occasionally are there policies in place to restrict or prefer certain agents.

1_mlHowever, new ways to control the cost of oncology care are emerging and are attracting attention. For example, pathways of care are considered a tool of growing relevance. Pathways, with or without risk sharing, are often mentioned as an oncology-specific cost containment tool, alongside other initiatives such as Oncology Care Models, changes in payment mechanisms for providers and, at least in part, value frameworks.

Despite the industry interest in pathways of care and other innovative oncology management tools, it is unclear what impact these new approaches will have on access at the local level. To explore this issue in-depth, MKO Global Partners organized a panel discussion with oncologists from different types of provider organizations.

Download White Paper

Learn about the three factors that emerged as key issues limiting payers' ability to manage oncology by downloading this paper.

 

Topics: MKO, Payers, ASCO